EIGER BIOPHARMACEUTICALS INC (EIGR)

Company Profile

Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

Company Info

EIGER BIOPHARMACEUTICALS INC

2155 Park Blvd

Palo Alto CALIFORNIA 94306

P: 16502799845

CEO: David A. Cory

Employees: 56

Website: https://www.eigerbio.com/